MEDIAN TECHNOLOGIES (ALMDT.PA) Stock Price, Forecast & Analysis
Europe - Euronext Paris - EPA:ALMDT - FR0011049824 - Common Stock
ALMDT.PA Key Statistics, Chart & Performance
The current stock price of ALMDT.PA is 3.09 EUR. In the past month the price increased by 11.75%. In the past year, price decreased by -4.33%.
ALMDT.PA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| NXU.DE | NEXUS AG | 36.14 | 1.23B | ||
| EQS.PA | EQUASENS | 18.08 | 655.34M | ||
| GPI.MI | GPI SPA | 22.59 | 489.74M | ||
| ALCGM.PA | CEGEDIM SA | N/A | 187.53M | ||
| AGFB.BR | AGFA-GEVAERT NV | N/A | 85.15M | ||
| AJ91.DE | DOCCHECK AG | 11.06 | 58.30M | ||
| M3V.DE | MEVIS MEDICAL SOLUTIONS AG | 9.92 | 45.14M | ||
| ALINS.PA | INTRASENSE SAS | N/A | 13.50M |
Related stock screener links
About ALMDT.PA
Company Profile
MEDIAN Technologies SA engages in the development and market of software publishing solutions and provision of services in the field of medical imaging in oncology. The company is headquartered in Valbonne, Paca and currently employs 241 full-time employees. The company went IPO on 2011-05-20. The firm develops lesion management solutions (LMS) to objectively measure and track cancerous or suspicious lesions, distribute a standardized oncologic report and centralize the lesion information for multidisciplinary review. The LMS line includes such products as LMS-Lung, a clinical application for the detection, evaluation and follow-up of lesions identified in CT images covering the chest; LMS-Track, a clinical application for the follow-up of oncology patients; and LMS-Liver, a clinical application for the initial evaluation and the follow-up of liver metastases and any other lesions identified in CT images covering the liver. The firm operates one subsidiary, Median Technologies Inc, based in the United States.
Company Info
MEDIAN TECHNOLOGIES
Les Deux Arcs - Batiment B 1800, Route des Cretes
Valbonne PACA FR
Employees: 250
Phone: 33493333777
MEDIAN TECHNOLOGIES / ALMDT.PA FAQ
What does MEDIAN TECHNOLOGIES do?
MEDIAN Technologies SA engages in the development and market of software publishing solutions and provision of services in the field of medical imaging in oncology. The company is headquartered in Valbonne, Paca and currently employs 241 full-time employees. The company went IPO on 2011-05-20. The firm develops lesion management solutions (LMS) to objectively measure and track cancerous or suspicious lesions, distribute a standardized oncologic report and centralize the lesion information for multidisciplinary review. The LMS line includes such products as LMS-Lung, a clinical application for the detection, evaluation and follow-up of lesions identified in CT images covering the chest; LMS-Track, a clinical application for the follow-up of oncology patients; and LMS-Liver, a clinical application for the initial evaluation and the follow-up of liver metastases and any other lesions identified in CT images covering the liver. The firm operates one subsidiary, Median Technologies Inc, based in the United States.
What is the stock price of MEDIAN TECHNOLOGIES today?
The current stock price of ALMDT.PA is 3.09 EUR. The price decreased by -2.22% in the last trading session.
Does ALMDT stock pay dividends?
ALMDT.PA does not pay a dividend.
How is the ChartMill rating for MEDIAN TECHNOLOGIES?
ALMDT.PA has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the Price/Earnings (PE) ratio of MEDIAN TECHNOLOGIES (ALMDT.PA)?
MEDIAN TECHNOLOGIES (ALMDT.PA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.16).
Can you provide the market cap for MEDIAN TECHNOLOGIES?
MEDIAN TECHNOLOGIES (ALMDT.PA) has a market capitalization of 113.46M EUR. This makes ALMDT.PA a Micro Cap stock.
What is the next earnings date for ALMDT stock?
MEDIAN TECHNOLOGIES (ALMDT.PA) will report earnings on 2026-04-27, after the market close.
ALMDT.PA Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to ALMDT.PA. When comparing the yearly performance of all stocks, ALMDT.PA is a bad performer in the overall market: 72.75% of all stocks are doing better.
ALMDT.PA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ALMDT.PA. ALMDT.PA may be in some trouble as it scores bad on both profitability and health.
ALMDT.PA Financial Highlights
Over the last trailing twelve months ALMDT.PA reported a non-GAAP Earnings per Share(EPS) of -1.16. The EPS increased by 10.04% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -112.72% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
ALMDT.PA Forecast & Estimates
11 analysts have analysed ALMDT.PA and the average price target is 8.81 EUR. This implies a price increase of 184.98% is expected in the next year compared to the current price of 3.09.
For the next year, analysts expect an EPS growth of 46.62% and a revenue growth 3.31% for ALMDT.PA